Preventive Medicine Center Hospital Israelita Albert Einstein, Sao Paulo, Brazil.
Ann Med. 2011;43(6):487-94. doi: 10.3109/07853890.2011.554428. Epub 2011 May 23.
INTRODUCTION. Hepatic steatosis due to non-alcoholic fatty liver disease is associated with obesity, dyslipidemia, insulin resistance, and type 2 diabetes. The Finnish Diabetes Risk Score (FINDRISC) is a prognostic screening tool to detect people at risk for type 2 diabetes without the use of any blood test. The objective of this study was to evaluate whether FINDRISC can also be used to screen for the presence of hepatic steatosis. PATIENTS AND METHODS. Steatosis was determined by ultrasound. The study sample consisted of 821 non-diabetic subjects without previous hepatic disease; 81% were men (mean age 45 ± 9 years) and 19% women (mean age 41 ± 10 years). RESULTS. Steatosis was present in 44% of men and 10% of women. The odds ratio for one unit increase in the FINDRISC associated with the risk of steatosis was 1.30 (95% CI 1.25-1.35), similar for men and women. The area under the receiver operating characteristics curve for steatosis was 0.80 (95% CI 0.77-0.83); 0.80 in men (95% CI 0.77-0.83) and 0.83 (95% CI 0.73-0.93) in women. CONCLUSIONS. Our data suggest that the FINDRISC could be a useful primary screening tool for the presence of steatosis.
简介。非酒精性脂肪性肝病引起的肝脂肪变性与肥胖、血脂异常、胰岛素抵抗和 2 型糖尿病有关。芬兰糖尿病风险评分（FINDRISC）是一种预测性筛查工具，用于在不进行任何血液检查的情况下，发现有患 2 型糖尿病风险的人群。本研究的目的是评估 FINDRISC 是否也可用于筛查肝脂肪变性。
患者和方法。通过超声确定脂肪变性。研究样本包括 821 名无既往肝脏疾病的非糖尿病患者；81%为男性（平均年龄 45 ± 9 岁），19%为女性（平均年龄 41 ± 10 岁）。
结果。男性中有 44%存在脂肪变性，女性中有 10%存在脂肪变性。FINDRISC 每增加一个单位，发生脂肪变性的风险比为 1.30（95%CI 1.25-1.35），男性和女性相似。用于诊断脂肪变性的受试者工作特征曲线下面积为 0.80（95%CI 0.77-0.83）；男性为 0.80（95%CI 0.77-0.83），女性为 0.83（95%CI 0.73-0.93）。
结论。我们的数据表明，FINDRISC 可能是一种有用的初筛工具，用于检测脂肪变性的存在。
